FDA approves AbbVie’s Mavyret for acute hepatitis C, expanding its use to patients 3 and older with or without cirrhosis after positive trial data.
FDA approves AbbVie’s Mavyret for acute hepatitis C, expanding its use to patients 3 and older with or without cirrhosis after positive trial data.
The UCW Newswire : Financial, Business and Tech NewsCopyright © Louis Velazquez. All Rights Reserved.